Pregled bibliografske jedinice broj: 683480
Urokinase Plasminogen Activator and Its Inhibitor Type-I as Prognostic Factors in Differentiated Thyroid Carcinoma Patients
Urokinase Plasminogen Activator and Its Inhibitor Type-I as Prognostic Factors in Differentiated Thyroid Carcinoma Patients // Otolaryngology : head and neck surgery, 149 (2013), 4; 533-540 doi:10.1177/0194599813496374 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 683480 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Urokinase Plasminogen Activator and Its Inhibitor Type-I as Prognostic Factors in Differentiated Thyroid Carcinoma Patients
Autori
Horvatić Herceg, Gordana ; Herceg, Davorin ; Kralik, Marko ; Kulić, Ana ; Bence-Žigman, Zdenka ; Tomić Brzac, Hrvojka ; Bračić, Irena ; Kusačić-Kuna, Sanja ; Prgomet, Drago
Izvornik
Otolaryngology : head and neck surgery (0194-5998) 149
(2013), 4;
533-540
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Urokinase-type plasminogen activator; type-I plasminogen activator inhibitor; differentiated thyroid carcinoma; prognosis; enzyme-linked immunosorbent assay
Sažetak
Objective was to investigate the prognostic value of urokinase-type plasminogen activator (uPA) and its inhibitor, type-I plasminogen activator inhibitor (PAI-I), in differentiated thyroid cancer. Cytosolic concentrations of uPA and PAI-I were determined in 105 patients with differentiated thyroid carcinoma and normal matched tissues using an enzyme-linked immunoassay (ELISA). Both uPA and PAI-I concentrations were significantly higher in differentiated thyroid tumors (uPA=0, 509±0, 767 and PAI-I = 6, 337±6, 415 ng/mg) compared to normal tissues (uPA=0, 237±0, 051, P < , 015, PAI-I, P < , 001). uPA and PAI-I were significantly higher if extrathyroidal invasion (uPA, P = , 015: PAI-I, P< , 001) or distant metastasis (PAI-I p< , 001) was present, as well as in tumors whose size exceeded 1 cm in diameter (uPA, p 0 , 002 ; PAI-I, P = , 001). Survival analysis revealed the significant impact of both uPA and PAI-I on progression-free survival (PFS) (82, 22 vs 49.478 months for patients with low and high uPA, respectively, P < , 001 ; 87, 068 vs 44, 964 months for patients with low and high PAI-I, respectively, P < , 001). Univariate analysis showed that gender, tumor size, tumor grade, extrathyroid invasion, local lymph node involvement, distant metastases, uPA, and PAI-I were significant predictors of PFS. However, multivariate analysis identified only distant metastases and tumor tissue uPA and PAI-I as independent prognostic factors. These findings indicate that high uPA an PAI-I levels represent independent unfavorable prognostic factors in patients with differentiated thyroid carcinoma.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
214-1080058-0488 - PROGNOSTIČKI POKAZATELJI BIOLOŠKOG PONAŠANJA KARCINOMA ŠTITNJAČE (Bence-Žigman, Zdenka, MZOS ) ( CroRIS)
Ustanove:
Klinički bolnički centar Zagreb
Profili:
Ana Kulić
(autor)
Davorin Herceg
(autor)
Marko Kralik
(autor)
Gordana Horvatić Herceg
(autor)
Irena Bračić
(autor)
Hrvojka Tomić-Brzac
(autor)
Zdenka Bence-Žigman
(autor)
Sanja Kusačić Kuna
(autor)
Drago Prgomet
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE